Review Article
Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature
Table 3
Clinical trials of 177Lu-DOTATATE and 90Y-DOTATOC in advanced NETs.
| Treatment regimen | Patients (number) | ORR (%) | Median PFS (months) | Criteria | Reference |
| Phase III studies | | | | | | NETTER-1 study | | | | | | 177Lu-DOTATATE | 116 | | Not achieved | RECIST | [83] | Octreotide LAR | 113 | | 8.4 | Phase I and II studies | | | | | | 177Lu-DOTATATE | 310 | 29 | 33 | RECIST | [80] | 177Lu-DOTATATE | 26 | 38 | | RECIST | [84] | 177Lu-DOTATATE | 12 | 17 | | RECIST | [85] | 177Lu-DOTATATE | 42 | 32 | 36 | RECIST | [86] | 90Y-DOTATOC | 58 | 23 | 17 | RECIST | [87] | 90Y-DOTATOC | 53 | 23 | 29 | RECIST | [88] | 90Y-DOTATOC | 90 | 4 | 16 | RECIST | [89] | 90Y-DOTATOC | 58 | 9 | 29 | RECIST | [90] | 90Y-DOTATOC | 21 | 29 | | RECIST | [91] |
|
|
ORR, overall response rate; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumors; LAR, long-acting release.
|